The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•14 April 2026•

1 min read

Pacira Data Shows EXPAREL Reduces Healthcare Costs in Joint Replacements

Key Facts

1Real-world data demonstrated that EXPAREL use in outpatient Total Hip and Knee Arthroplasty is associated with lower total healthcare costs.

2Findings were presented to highlight the drug's economic efficiency over various follow-up periods.

Pacira BioSciences has presented new real-world evidence demonstrating that its flagship product, EXPAREL, significantly reduces total healthcare expenditures. The findings indicate that the drug's use in outpatient Total Hip and Knee Arthroplasty is associated with enhanced economic efficiency across various follow-up periods. By showcasing these cost-saving benefits, the company aims to strengthen its value proposition to healthcare providers and insurance payers. This economic validation supports broader clinical adoption and could potentially lead to improved reimbursement terms. The positive data is expected to drive revenue growth for Pacira by proving the drug's financial viability alongside its clinical performance. Overall, the report reinforces EXPAREL's competitive position in the orthopedic surgical market as a cost-effective solution.